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ABSTRACT 
 
CANNABINOIDS SUPPRESS THE INNATE IMMUNE RESPONSE TO 
THE PERIODONTAL PATHOGEN PORPHYROMONAS GINGIVALIS IN 
GINGIVAL EPITHELIAL CELLS 
By 
Rajarshi Guha Niyogi 
June 6  2016 
Marijuana is widely used in the United States for recreational and 
medicinal purposes. Despite the proposed beneficial effects of 
cannabis on certain medical conditions, there is also a concern there is 
also a concern over negative health consequences of marijuana 
smoking. Recently, cannabis use has been established as a dose-
related risk factor for chronic periodontitis. Although the induction / 
exacerbation of chronic periodontitis in marijuana users has been 
established epidemiologically, the mechanisms underlying such 
predisposition are still unknown. It has long been suggested that 
marijuana has anti-inflammatory properties, while human epithelial 
cells are known to express cannabinoid receptor type 2 (CB2). 
Therefore, we hypothesized that marijuana-derived cannabinoids may 
suppress the innate immune response, altering the ability of gingival 
epithelial cells to respond appropriately to bacterial stimuli (the 
classic TLR4 ligand, E. coli LPS; and the major periodontal 
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pathogen, Porphyromonas gingivalis). More specifically, we 
hypothesized that predominant phytocannabinoid subtypes 
(cannabidiol [CBD], cannabinol [CBN], or tetrahydrocannabinol 
[THC]) at physiologically relevant doses (0 - 10µg/ml) would 
suppress proinflammatory cytokine production in LPS- (0-1µg/ml) or 
P. gingivalis (MOI, 10:1) exposed telomerase immortalized human 
gingival keratinocytes (TIGK cells) in a CB2-related manner. We also 
hypothesized that marijuana-derived cannabinoids may influence the 
viability of both epithelial (TIGK cells, as assessed by Trypan blue 
exclusion) and representative oral bacteria (P. gingivalis, Treponema 
denticola and Filifactor alocis, growth curves monitored by optical 
density). Higher doses (>5 µg/ml) of marijuana derived cannabinoids 
(CBD, CBN or THC) inhibited the growth of P. gingivalis (p < 0.001) 
and F. alocis (p < 0.001), relative to unexposed bacteria, whereas T. 
denticola growth was resistant to all cannabinoid doses tested (1- 10 
µg/ml, p > 0.05).. TIGK cells were non-viable when exposed to high 
cannabinoid concentrations (> 10 µg/ml).Sub-lethal (1 -5 µg/ml) 
doses of each cannabinoid subtype suppressed the production of IL-8 
and IL-6 but enhanced IL-10 release in P. gingivalis or LPS-
stimulated TIGKs (all p < 0.001). Treatment with the CB2 inhibitor, 
JTE907, did not rescue cannabinoid-induced immune suppression, 
suggesting that alternative cannabinoid receptors, such as CB1, 
GPR55 or A2A receptors, may be associated with the anti-
 
 
inflammatory function of marijuana-derived cannabinoids. If the 
phenomena of (i) cannabinoid induced epithelial toxicity; (ii) growth 
restriction of a sub-population of bacterial species in the oral biofilm; 
and (iii) innate suppression in gingival epithelial cells, established 
herein, occur in vivo, they are likely to help explain increased 
susceptibility to periodontal diseases in cannabis users. To expand, 
the epithelial barrier may be compromised in marijuana smokers, 
facilitating bacterial entry and more efficient diffusion of microbial 
toxins into the gingival tissues; marijuana-derived cannabinoids may 
promote microbial dysbiosis; and a suppressed pro-inflammatory 
epithelial response to bacterial stimuli may promote immune evasion, 
colonization and persistence by pathogenic bacteria. These data 
provide some of the first mechanistic insights into cannabinoid 
associated periodontal diseases. Such mechanistic advance are critical 
if novel therapeutics to prevent chronic periodontitis in marijuana 
users are to be developed. Further, an improved understanding of the 
immuneregulatory properties of cannabinoids will be useful in the 
development of therapeutics for the containment of inflammation, in 
general
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CHRONIC PERIODONTITIS 
 
Chronic periodontitis is an inflammatory condition affecting a large 
section of the global adult population. It is a disease which affects the 
supporting structures of the teeth causing marked degeneration and 
destruction of these structures, potentially leading to the exfoliation of 
the teeth. The host immune response plays a critical role in the 
progression of chronic periodontitis. About 47.2% of the population 
is affected by the disease and consumes $14 billion as health cost in 
United States1, 2. Periodontitis is usually seen affecting the adult 
population more although an acute aggressive variant is also noted in 
young adults which is characterized by the extensive bone loss around 
the lower incisors and first molars. Chronic periodontitis is 
multifactorial disease and its progression depends on the interplay of 
both intrinsic factors, like the immune response, and extrinsic 
environmental factors, like smoking and oral hygiene habits3. 
 
In humans, the epithelial layer of mucosal surface represents an initial 
interface for colonizing microorganisms4. In addition to constituting a 
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physical barrier to the entry of organisms, epithelial cells can sense 
and respond to the presence of bacteria through an elaborate signaling 
network that can communicate information to the underlying immune 
effector cells5, 6. Environmental factors such as smoking can expose 
the epithelial mucosa to numerous compounds which may 
compromise these essential signaling pathways leading to a 
suppressed innate response which predisposes to periodontal 
pathogen infection, suppresses pathogen clearance, and increases 
susceptibility to chronic periodontit
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IMMUNITY AND INFLAMMATION 
 
Immunity is defined as the ability of the body to resist or fight off 
infection and disease. Innate immunity, also known as the nonspecific 
immune system, is the first line of defense8. It is a part of the overall 
immune system that comprises the cells and mechanisms that defend 
the host from infection by other organisms. This means that the cells 
of the innate system recognize and respond to pathogens but do not 
confer long-lasting or protective immunity to the host. Innate immune 
systems provide immediate defense against infection6. The major 
functions of the innate immune system include: 
• Recruiting immune cells to sites of infection, through the 
production of chemical factors, including specialized chemical 
mediators called cytokines. 
• Activation of the complement cascade to identify bacteria, 
activate cells, and promote clearance of antibody complexes 
or dead cells. 
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• The identification and removal of foreign substances present 
in organs, tissues, the blood and lymph, by specialized white 
blood cells. 
 
• Activation of the adaptive immune system through a process 
known as antigen presentation. 
• Acting as a physical and chemical barrier to infectious agents. 
Adaptive immunity on the other hand refers to antigen-specific 
immune response. The adaptive immune response is more complex 
than the innate. The antigen first must be processed and recognized. 
Once an antigen has been recognized, the adaptive immune system 
creates an army of immune cells specifically designed to attack that 
antigen9. 
Inflammation is part of the complex biological response of vascular 
tissues to harmful stimuli such as pathogens, damaged cells and other 
irritants. It is a protective response involving host cells, blood vessels, 
proteins and other mediators that are intended to eliminate the initial 
cause of cell injury and insult10. The classical signs of inflammation 
are pain, heat, redness, swelling, and loss of function. Inflammation is 
a stereotypical response, and therefore it is considered as a 
mechanism of innate immunity as compared to adaptive immunity11, 
which is specific for each path
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THE PERIODONTAL PATHOGEN - P. GINGIVALIS 
 
The periodontal pathogen, P. gingivalis is an anaerobic, Gram negative 
bacterium that is considered to be a major etiological factor in chronic 
periodontitis12. It is a non-spore forming and belongs to the phylum 
Bacteroidetes. This opportunistic pathogen is known to cause disease by 
promoting shifts in the oral flora that lead to inflammation and bone loss13, 
14. P. gingivalis grows in vitro by forming smooth, raised colonies on 
blood agar plates. The colonies appear creamy to white in color initially 
and turn to black in three to four days with a specific unpleasant odor. 
Bacterial colonies turn black due to the uptake of hemin from blood in the 
plates15. Morphologically, the bacterium appears cocco-bacillar (small 
rods) and is asacchrolytic and thus metabolizes the host proteins for its 
growth and survival. 
P. gingivalis have been considered as a “keystone” pathogen in 
periodontal disease as it has a disproportionately large effect on its 
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biofilm community when compared to its abundance16. The presence 
of low numbers of P. gingivalis was required for the significant 
increase in oral microbiota which was associated with disease(PSD 
model)17 .The total percentage of abundance of P. gingivalis in few  
cases was found to be less than 0.01% of oral commensal bacteria in 
humans. The bacterium is also responsible for altering the normal 
host-bacterial inter play in the periodontium18. It suppresses the 
complement system and there by provides an excellent niche for other 
commensal bacteria to grow and invade further, leading to 
periodontitis. 
The polysaccharide capsule is a potent virulence factor in P. 
gingivalis. It has mechanisms that down-regulate specific aspects of 
host immune response and thereby survives proficiently by masking 
the host immune system19, 20.The capsule of P. gingivalis is thought to 
make a     significant contribution to virulence of the bacterium. The 
non-encapsulated strains would probably be less efficient in 
progression of periodontitis due to their reduced ability of both 
biofilm participation and tissue invasiveness21. It is indicated that the 
capsule plays multiple roles in the virulence of P. gingivalis. These 
include reduction of the host immune response to the bacterium, 
reduced phagocytosis, and increased bacterial survival21, 22. 
P.gingivalis has long been considered an important member of the 
periodontopathic microbiota involved in periodontal disease 
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progression, bone and tissue destruction. P. gingivalis, because of  its 
ability to  produce  significant numbers  of  potential virulence  
molecules,  is  considered  an  important pathogen in this progression 
from health to disease23 
P. gingivalis has two dominant kinds of fimbriae, major and minor.  
The fimbriae play a critical part in the bacterial virulence. Six variants 
of major fimbriae are known to exist depending on the genetic 
diversity of the gene coding them (fim A). Type II fimbriae are 
known to be associated with higher adhesion and invasive potential in 
comparison to others. The minor fimbriae (mfa1) aid in cohesion with 
other bacteria (Streptococcus gordonii) and thereby biofilm 
development and growth24. The lipopolysaccharide (LPS) of P. 
gingivalis is considered to be a potent virulence factor too. The LPS 
stimulates the host inflammatory pathway by interacting with the 
Toll-like Receptor 4 (TLR 4)25, 26. Interestingly, the LPS of P. 
gingivalis exists in varying chemical structure, each with different 
properties. The tetra-acylated form of LPS is a TLR 4 antagonist 
whereas the penta-acylated form is a TLR 4 agonist. The shift from 
penta-to tetra-acylated forms is regulated by the presence of hemin 
(increased hemin levels up regulate tetra-acylation)27. 
Gingipains are cysteine proteases that provide maximal advantage to 
the bacterium in the exacerbation of periodontal disease. More than 
85% of the proteolytic activity of the bacterium is accountable to the 
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existence of gingipains. These are encoded by three genes rgpA, rgpB 
and kgp. rgpA and  rgpB specifically cleave at arginine peptides and 
kgp at lysine residue28. These play a multi-functional role in the 
bacterium and are thereby considered vital for the survival of the 
pathogen. rgpA is required for the maturation of long/major 
fimbriae29. Thus, gingipains indirectly play a role in the attachment of 
P. gingivalis in the biofilm. These proteases also enhance the 
nonfimbrial adhesion mechanism by binding closely to epithelial 
cells, fibroblasts and extra cellular matrix proteins including 
fibrinogen, type V collagen, laminin and fibronectin. The destruction 
of extra cellular matrix leading to progression of periodontitis is 
attributed to gingipains30. Additionally, these proteolytic enzymes 
help the bacterium in nutrient acquisition. Iron uptake by P. gingivalis 
is attributed to the presence of hemagglutinins, which in turn are 
regulated by gingipains31. 
Furthermore, the bacterium also obtains peptides as a source of 
carbon and nitrogen through gingipains. The gingipains, being 
endonucleases, cleave the host proteins which are then converted to 
di-tripeptides by   the respective peptidases32. Finally, the di-tri 
peptides are transported into the cell and then metabolized for energy 
needs. Gingipains also neutralize and subvert the host immune 
responses by cleaving several products in the pathway of complement 
activation in the host33. Pathogenic strains of P. gingivalis are active 
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participants of the complex oral biofilms. Bacterial interactions 
through quorum sensing, cross feeding, co-aggregation, contact 
dependent signaling aid in the metabolic exchange, alteration of gene 
expression and efficient survival of the organism in the biofilms34. 
The interplay not only effectively improves the pathogenicity of P. 
gingivalis but also of the entire communityThe initial colonization of 
P. gingivalis in the oral cavity occurs by the adhesion to primary 
colonizers, such as Streptococcus gordonii24. The minor fimbrial 
antigen (mfa1) of P. gingivalis adheres to the streptococcal antigens I 
and II. The interactions also aid in the survival of the bacteria in 
adverse conditions. The ability of the bacterium to co-aggregate and 
associate with several other bacteria in the biofilm, in turn up 
regulates the virulence of the entire community17. P. gingivalis 
invades several host cell types including gingival epithelial cells, 
endothelial cells and smooth muscle cells35. 
The inter-cellular spreading of P. gingivalis is through a unique 
mechanism. The bacteria spread between the cells through actin based 
membrane protrusions. This mode of inter-cellular translocation 
prevents the bacterium from being exposed to the host’s immune 
responses. Studies on the invasion process have suggested the 
presence of a unique mechanism of invasion into the host. The serine 
phosphatase enzyme of P. gingivalis is involved in this process. The 
enzyme activity leads to dephosphorylation and activation of cofilin, 
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a protein responsible for actin remodeling through de 
polymerization36. Although the bacterium can spread without cell-to-
cell contact, the tight cell contact hastens the invasion process. P. 
gingivalis establishes a long term cohabitation with gingival epithelial 
cells, which in turn can survive up to eight days after infection with 
the bacteria37. Inside the cell, the bacteria migrate to the perinuclear 
area and accumulate. The bacterium resides in the host cells, 
overcoming the major challenges like oxidative stres
11 
 
OTHER REPRESENTATIVE PERIODONTAL PATHOGENS 
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The other fast emerging periodontal pathogen is F. alocis41. F. alocis 
is one of a few bacteria that is associated with multiple oral diseases 
including periodontitis, localized aggressive periodontitis, 
endodontitis and peri-implantitis. Its relative abundance in the 
periodontal pocket of patients with periodontitis may support the 
hypothesis to include F. alocis as a diagnostic marker organism42. 
This organism has unique potential virulence characteristics such as 
resistance to oxidative stress and genes coding for a well-developed 
amino acid metabolic pathway that can modulate multiple changes to 
the oral microbial community and the host cell proteome that 
collectively can lead to the disease process43. Multiple studies have 
documented the increasing incidence and importance of F. alocis ( In 
comparison to the other traditional periodontal pathogens, the high 
incidence of F. alocis in the1 periodontal pocket compared to its 
absence in healthy or periodontitis resistant patients has highlighted 
its importance in the infectious disease process. F. alocis has also 
been discovered in the canals of root-filled teeth with periapical 
lesions and is associated with signs and symptoms of endodontic 
infections44. It has also been identified as one of the prevalent 
phylotypes in cases of failed endodontic treatment. P. gingivalis 
ATCC 33277 co-cultured with F. alocis showed significant increase 
in biofilm formation. This enhanced biofilm forming capacity may be 
due to the ability of both species to auto aggregate and express unique 
13 
 
components. This could indicate a commensal relationship between 
F. alocis and P. gingivalis. Thus, F. alocis and P. gingivalis, each 
with different growth rates, could form a mixed species biofilm and 
coexist. As a result, F. alocis proteins could enable P. gingivalis to 
proliferate and disseminate from these biofilms thus facilitating its 
virulence45. 
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CANNABINOIDS: 
 
Cannabis, commonly known as marijuana, is a product of the Cannabis sativa 
plant and the active compounds from this plant are collectively referred to as 
cannabinoids46. Cannabinoids are a group of compounds that mediate their 
effects through cannabinoid receptors. The discovery of 
Δ9tetrahydrocannabinol (THC) as the major psychoactive principle in 
marijuana, as well as the identification of cannabinoid receptors and their 
endogenous ligands, has led to a significant growth in research aimed at 
understanding the physiological functions of cannabinoids47. Cannabinoid 
receptors include CB1, which is predominantly expressed in the brain and 
mediates the psychotropic side effects, and CB2, which is primarily found on 
the cells of the immune system48. Other sub-types of cannabinoids include 
cannabidiol (CBD) and cannabinol (CBN). The fact that both CB1 and CB2 
receptors have been found on immune cells suggests that cannabinoids could 
play an important role in the regulation of the immune system49. 
Cannabinoids are potent anti-inflammatory agents and they exert their effects 
through suppression of cytokine production, inflammatory cell migration, and 
induction of T-regulatory cells and induction of apoptosis50. 
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The various mechanisms through which cannabinoids bring about 
anti-inflammatory action are as follows: 
A) CANNABINOIDS MODULATE CYTOKINE PRODUCTION: 
Cytokines are the signaling proteins synthesized and secreted by 
immune cells upon stimulation. They are the modulating factors 
that balance initiation and resolution of inflammation. One of the 
possible mechanisms of immune control by cannabinoids during 
inflammation is the dysregulation of cytokine production by 
immune cells51, 52. Furthermore, cannabinoids may affect immune 
responses and host resistance by perturbing the balance between 
the cytokines produced by T- helper subsets, Th1 and Th227. 
Earlier studies have showed that THC have produced a 
concentration-dependent inhibition of T cell proliferation53. The 
production of cytokines by stimulated T cells plays a critical role 
in amplifying and targeting immunity. When activated T cells 
mature into Th1 cells, they secrete IL-2 and IFN-α and potentiate 
cell-mediated immunity by enhancing T cell proliferation and 
effector functions, up-regulating MHC expression, promoting 
IgG2a isotype switching, and activating effector cells such as NK 
cells and macrophages. In contrast, when activated T cells acquire 
a Th2 phenotype, they secrete IL-4, IL-5 and/or IL-10, and 
16 
 
potentiate allergic/atopic antibody responses while suppressing T 
cell proliferation and cell mediated immunity53. 
B) CANNABINOIDS MODULATE INFLAMMATORY-CELL 
MIGRATION: 
The accumulation of leukocytes in tissues contributes to a wide 
variety of diseases; these 'molecular codes' have provided new targets 
for inhibiting tissue-specific inflammation. However, immune cell 
migration is also critically important for the delivery of protective 
immune responses to tissues. Thus, the challenge for the future will 
be to identify the trafficking molecules that will most specifically 
inhibit the key subsets of cells that drive disease processes without 
affecting the migration and function of leukocytes required for 
protective immunity. Inflammatory migration of immune cells is 
involved in many human diseases. Identification of molecular 
pathways and modulators controlling inflammatory migration could 
lead to therapeutic strategies for treating human inflammation-
associated diseases. Although the exact mechanism is unknown but 
studies have highlighted several signaling pathways that may 
suppress the leukocyte inflammatory migration. Cannabinoids have 
been found to suppress inflammatory cell migration in some studies 
but exact mechanism still needs to be established. Few possible 
mechanism through which cannabinoids can suppress inflammatory 
cell migration through CB2 receptor are as follows: 
17 
 
• One of the studies have shown that CB2 receptor agonist have an 
inhibitory action on the JNK/c-Jun/Alox5 Pathway54. The cooperative 
effect between the Cnr2 agonist and the Alox5 inhibitor of leukocyte 
inflammatory migration implicates a new strategy for developing 
anti-inflammation therapies. Investigating the effect of a combined 
therapy with Cnr2 agonist and Alox5 inhibitor would be valuable in 
treating human diseases such as multiple sclerosis, rheumatoid 
arthritis, atherosclerosis, asthma, or even cancer. 
• It has also been seen that cannabinoid receptor 2 agonist reduces 
immune cell migration in neuro inflammation via inhibition of matrix 
metalloproteinase-955 .The study was done using murine model and 
dendritic cell to conduct migration assay and see the effect of 
cannabinoids on the migration of these cells were studied. The 
Cannabinoid mediated suppression of leukocyte adhesion and 
migration resulting from an inhibition of TH1cell cytokine 
production. 
 
C) CANNABINOIDS REGULATE HELPER T CELLS: 
Cannabinoids have a Th-cell biasing effect, in which Th1-cell 
activity is suppressed and Th2-cell activity is increased56. 
From prior studies, it seems that cannabinoids bias the 
immune response away from Th1-cell immunity and that 
cannabinoid receptors are involved in this process30. 
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Treatment with cannabinoids has been shown to alter the 
expression of specific transcription factors, the expression of 
the Th2-cellpromoting transcription factor GATA-binding 
protein 3 (GATA3) has been found to be increased by 
treatment with cannabinoids whereas the production of IL-2 
expression-promoting transcription factors is suppressed by 
treatment with cannabinoids. The selective suppression of 
Th1-cell immunity by these drugs supports their potential use 
in the treatment of chronic inflammatory diseases. There is 
now ample evidence that cannabinoids and other GPCR 
agonists can modulate the development of Th cells. In the case 
of cannabinoids, it is possible that CB1 and CB2 may be 
differentially expressed on different subpopulations of APCs 
and Th cells57. This selective expression could lead to an 
increase in Th2 development and a decrease in the 
development of Th1 cells, resulting in suppression of innate 
immunity and increased adaptive immunity49. Continued 
research on the distribution and function of cannabinoid 
receptors as well as the production of endocannabinoids by 
different immune cells will provide greater insight into these 
mechanisms. One of the objective of the future studies should 
be not only to evaluate the therapeutic potential of 
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cannabinoids but also innate immune suppression brought 
about through cell biasing 
D) CANNABINOIDS HAVE AN APOPTOTIC EFFECTS ON 
IMMUNE CELL 
POPULATIONS: One major mechanism of immune suppression by 
cannabinoids is the induction of cell death or apoptosis50. Apoptosis 
is defined as the programmed cell death caused by both intrinsic and 
extrinsic factors. Apoptosis eliminates damaged, harmful and 
unwanted cells, it is significant in biological processes including 
development, morphogenesis, and homeostasis. During apoptosis, 
many morphological changes occur such as membrane blebbing, cell 
shrinkage, mitochondria leakage, and nuclear fragmentation. 
Molecular changes underlie these morphological changes, and they 
make up the two different pathways of apoptosis: (1) intrinsic 
pathway – via mitochondria, and (2) extrinsic pathway – through 
death receptors. 
Cannabinoids shows a wide range of apoptotic effect on different 
types of immune cells like B cells, T cells, antigen presenting cells 
like (Dendritic cells) and the malignant immune cells. In T cells prior 
studies have shown suppression of T cell proliferation. The 
endogenous cannabinoids have shown to induce apoptosis in the T 
cell culture. This was mostly bought about by the BCl-2 and the 
caspase activity. Systemic administration of THC has shown 
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suppressed proliferation of B cells, T cells and macrophages in 
spleen. CBD has shown apoptosis of CD4/ and CD8/ in a time and 
dose dependent manner. 
Although the knowledge about the cannabinoids and their effect 
on innate response in gingival epithelial cells in context to oral cavity 
is limited. Few prior studies have shown that cannabinoid receptors 
especially CB1 play an important role in suppressing innate immunity 
through the TLR pathways utilizing the endocannabinoid ligands58. 
Studies have also shown consistent expression of CB2 receptors in 
the gingival epithelial cells and the periodontal ligament cells59, 
60.Multiple studies have established marijuana as an important risk 
factor for chronic periodontitis in humans61, 62. Moreover marijuana 
use appears to predispose teenagers and young adults to alveolar bone 
and attachment loss63. Animal model studies have shown that 
cannabinoids also predispose animals to destructive periodontal 
disease. Rodents with ligated teeth exposed to marijuana smoke for 
only eight mins per day develop more extensive alveolar bone loss 
than ligated, unexposed animals64, while reduced bone healing around 
implants has also been demonstrated in animals65. 
In conclusion we see that activation of CB2 may have an anti-
inflammatory and anti-resorptive effects on LPS and P. gingivalis-
stimulated TIGK cells. These findings suggest that activation of CB2 
might be an effective therapeutic strategy for the treatment of 
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inflammation and alveolar bone resorption in periodontitis. Our study 
provides a potential rationale for the use of exogenous factors such as 
CB2-specific agonists as drugs in the treatment of periodontitis. 
Further studies are required to corroborate the effect of CB2 
activation on periodontitis in vivo. 
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TELOMERASE IMMORTALIZED GINGIVAL KERATINOCYTES 
(TIGKS) 
 
Gingival keratinocytes are used in model systems to investigate the 
interaction between periodontal bacteria and the epithelium in the 
initial stages of the periodontal disease process. The gingival 
epithelium usually classified into sulcular epithelium, junctional 
epithelium (nonkeratinized) and oral gingival epithelium 
(keratinized). The junctional epithelium lies in the sulcus between the 
soft and hard tissues and has a unique structure. The junctional 
epithelium has intercellular spaces that create spaces for the immune 
cells to migrate into the gingival sulcus. They are the first to 
encounter the colonizing bacteria in the oral cavity and are thereby, 
wellknown to play an important role in the host bacterial 
environment. Several studies have shown the immunological 
modulation brought about by the epithelial cells the first line of 
defense is essential for the initiation and progression of periodontitis. 
Primary gingival epithelial cells have their limitations. Primary 
gingival epithelial cells are obtained from the gingival tissue of 
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healthy human subjects and then isolated and cultured in the 
laboratory .Primary gingival epithelial cells have been used as model 
systems for several studies. However, the cells have a finite lifespan   
and cease to grow after nine passages approximately and are then 
challenged to senescence and stop replicating any further. The limited 
life span poses a huge disadvantage in their usage. Also, there can be 
dissimilarities in their phenotype from donor to donor, questioning 
their use in in vitro experiments. To overcome the issue of finite life 
span, epithelial cells immortalized with viral proteins also known as 
the telomerase-immortalized human gingival epithelial cell line 
exhibited the capacity to undergo several passages. Thus a cell line 
which was comparable to the in vitro behavior of human GEC was 
developed66. 
Thus, we can summarize that with the literature supporting the use of 
cannabis as a potent anti-inflammatory agent over several decades in 
chronic inflammatory conditions, it would be interesting to find out 
the nature and extent of cannabinoid-induced immune suppression in 
epithelial cells and determine the mechanistic basis for this effect.  
While clearly relevant to periodontal disease, such innate suppression 
is likely to be a central mediator of inflammation per se and, thus, 
have implications far beyond the oral cavity. 
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CHAPTER 2: MATERIALS AND METHODS 
BACTERIAL CULTURE 
Porphyromonas gingivalis ATCC 33277, Filifactor alocis ATCC 
35896 and Treponema denticola ATCC 35405 were purchased from 
the American Type Culture Collection (Manassas, VA) and 
maintained as frozen stocks.  P. gingivalis was grown in Gifu 
anaerobic medium (GAM; Nissui Pharmaceutical, Tokyo, Japan).  F. 
alocis was grown in brain heart infusion (BHI) medium (Becton 
Dickinson, Sparks, MD) supplemented with L-cysteine (0.1%) and 
arginine (20%, both Sigma-Aldrich, St. Louis, MO). T. denticola was 
grown in tryptone-yeast extract-gelatin-volatile fatty acid-heat 
inactivated rabbit serum (TYGVS) medium. A broth medium  had the 
following composition (per liter): tryptone (Difco Laboratories, 
Detroit, Mich.), 10.0 g; brain heart infusion broth, 5.0 g; yeast extract, 
10.0 g; gelatin, 10.0 g; (NH4)2SO4, 0.5 g; MgSO4- 7H2O, 0.1 g; 
K2HPO4, 1.13 g; KH2PO4, 0.9 g; and NaCl, 1.0 g (TYGVS 
medium). The pH was adjusted to 7.2 with 4 N KOH before the 
autoclaving of the medium. The following ingredients were mixed, 
neutralized with KOH, sterilized by filtration, and added aseptically 
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to the autoclaved medium containing (final concentration, per liter): 
glucose, 1.0 g; cysteine hydrochloride, 1.0 g; thiamine 
pyrophosphate, 0.0125 g; sodium pyruvate, 0.25 g; acetic acid, 0.27     
ml; propionic acid, 0.10 ml; n-butyric acid, 0.064 ml; n-valeric acid, 
0.016 ml; isobutyric acid, 0.016 ml; isovaleric acid, 0.016 ml; DL-
methylbutyric acid, 0.016 ml; and heat-inactivated rabbit serum, 10% 
(vol/vol). P. gingivalis, F. alocis, and T. denticola were grown under 
anaerobic conditions (80% N2, 10% H2, and 10% CO2) at 370c. 
Growth was monitored by tracking optical density at a wavelength of 
600 nm. T. denticola ASLM, which had been isolated from human 
subgingival plaque, was maintained and grown at 34°C in an 
atmosphere of 85% N2, 10% H2, and 5% CO2 in an anaerobic 
chamber (Coy Manufacturing, Ann Arbor, Mich.) in a broth medium 
which had the following composition (per liter): tryptone (Difco 
Laboratories, Detroit, Mich.), 10.0 g; brain heart infusion broth, 5.0 g; 
yeast extract, 10.0 g; gelatin, 10.0 g; (NH4)2SO4, 0.5 g; MgSO4- 
7H2O, 0.1 g; K2HPO4, 1.13 g; KH2PO4, 0.9 g; and NaCl, 1.0 g 
(TYGVS medium). The pH was adjusted to 7.2 with 4 N KOH before 
the autoclaving of the medium. The following ingredients were 
mixed, neutralized with KOH, sterilized by filtration, and added 
aseptically to the autoclaved medium containing (final concentration, 
per liter): glucose, 1.0 g; cysteine hydrochloride, 1.0 g; thiamine 
pyrophosphate, 0.0125 g; sodium pyruvate, 0.25 g; acetic acid, 0.27 
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ml; propionic acid, 0.10 ml; n-butyric acid, 0.064 ml; n-valeric acid, 
0.016 ml; isobutyric acid, 0.016 ml; isovaleric acid, 0.016 ml; 
DLmethylbutyric acid, 0.016 ml; and heat-inactivated rabbit serum, 
10% (vol/vol). 
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CELL CULTURE 
Telomerase immortalized gingival keratinocytes (TIGKs) were 
maintained as frozen stocks and cultured in Dermalife-K serum free 
keratinocyte culture medium (Lifeline cell technology, Walkersville, 
MD) containing the supplements, transferrin 5ug/ml, rh TGF-α 
0.5ng/ml, rh insulin 5ug/ml, epinephrine 1.0uM, L- glutamine 6mM, 
hydrocortisone 100ng/ml and extract-P 0.4%66. Cells were grown in a 
humidified chamber at 37°C, 5% CO2. Medium was changed every 2-
3 days and cells were passaged when 80-90% confluent. Cells were 
passaged by washing twice with phosphate-buffered saline (PBS) and 
incubating with 0.05%Trypsin/0.53mM EDTA at 37°C for 5-10 
minutes until cells lifted from the surface of the flask. Dermalife-K 
serum free keratinocyte culture medium was added to the cell 
suspension to inhibit the enzymatic activity of trypsin/EDTA, and 
cells were centrifuged at 9.7 g for 10 minutes. The supernatants were 
removed, the cell pellet re-suspended in medium and re-seeded at 1.0 
x 106 cells/T75 flask. The cells were seeded into 6well plates at 30% 
confluence and infected when 80% confluence was attained (approx. 
1.0 x 106 cells/well). 
 
28 
 
 
CYTOKINE EXPRESSIONS PATTERNS IN GINGIVAL EPITHELIAL 
CELLS 
TIGK cells were exposed, or not, to three cannabinoid subtypes 
[cannabidiol, cannabinol, or tetrahydrocannabinol; 1, 5 or 10 µg /ml] 
and epithelial viability was determined using the Trypan blue 
exclusion test. TIGKs (1 x 106 cells per well) were also challenged, or 
not, with P. gingivalis at MOI of 10 in the presence or absence of 
cannabinoids [cannabidiol, cannabinol, or tetrahydrocannabinol; 0, 1, 
or 5 µg /ml]. Bacterial cells were harvested at mid to late log phase.   
Cytokine (IL-6, IL-8 and IL-10) induction and release was 
determined by ELISA, according to the manufacturer’s instructions. 
TIGKs (1 x 106 cells per well) were also challenged with LPS at 
concentration of 1ug/ml in the presence or absence of cannabinoids 
[cannabidiol, cannabinol, or tetrahydrocannabinol; 0, 1, or 5 µg /ml]. 
Cytokine (IL-6, IL-8 and IL-10) induction and release was again 
determined by ELISA, according to the manufacturer’s instructions. 
To check for the functional significance of the CB2 receptor, a CB2-
specific pharmacological inhibitor, JTE907 (Tocris, Bioscience), was 
used at concentration of 5 µg/ml. Cells were exposed for 30 min to 
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the inhibitor then exposed to cannabinoid subtypes for 2 hours and 
then exposed to of bacterial stimulant LPS 1ug/ml and P. gingivalis at 
MOI of 10:1 and incubated overnight.  Twenty hour cell-free 
supernatants were collected by centrifugation at 9.7 x g for 4 mins. 
All experiments were performed in triplicate. 
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STATISTICAL ANALYSIS 
Statistical analyses were performed using Graph Pad Prism 6 (Graph 
Pad Software, San Diego, CA). Data are presented as mean, standard 
deviation of the mean (SD). Differences were analyzed with one-way 
ANOVA and Student t test, as appropriate. Statistical significance 
was set at p < 0.05. 
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RESULTS 
3.1 Cannabinoids, P. gingivalis and TIGK cell viability 
HIGH CONCENTRATIONS OF CANNABINOIDS ARELETHAL TO TIGK CELLS 
To investigate the influence of three archetypal cannabinoids on 
TIGK viability, we exposed TIGK cells to various concentrations of 
cannabidiol, cannabinol and tetrahydrocannabinol. As shown in 
Figure 1, each cannabinoid subtype significantly lowered TIGK 
viability at concentrations of 10 µg/ml, as determined by Trypan blue 
exclusion. However, TIGK viability was not influenced by 
cannabinoid concentrations of 5 µg/ml or less. 
                                                        
                                Figure 1A                                               Figure 1B 
                                          
                                                              Figure 1C 
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FIGURE 1: Viability of cannabinoid-exposed TIGK cells. 
 
TIGK viability following exposure to (A) CBD, (B) CBN or (C) THC, at the 
cannabinoid   concentrations noted, was determined by Trypan blue 
exclusion. 
*** p < 0.001 compared to the untreated control. 
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P. gingivalis DOESNOT ALTER VIABILITY OF 
CANNABINOID EXPOSED TIGK CELLS 
  
The viability of cannabinoid-exposed and control TIGKs were also 
monitored in presence and absence of P. gingivalis (MOI 10:1), 
again, by Trypan blue cell exclusion assay. The data presented in 
Figure 2 confirm that each cannabinoid subtype significantly 
suppressed TIGK viability at concentrations of 10 µg/ml, while TIGK 
viability was not influenced by cannabinoid concentrations of 5 µg/ml 
or less. P. gingivalis did not influence TIGK viability in the presence 
or absence of cannabinoids. Therefore, 0-5 µg/ml cannabinoid dosing 
regimens and bacterial infections at MOI 10:1 were employed in the 
remainder of the experiments. 
                              
                   Figure 2A                                                          Figure 2B                                                                     
34 
 
                                               
                                                     Figure 2C                                         
                                       
FIGURE 2: P. gingivalis does not influence the viability of 
cannabinoid-exposed TIGK cells.  
TIGK viability following exposure to CBD, CBN or THC at (A) 1 
µg/ml, (B) 5 µg/ml or (C) 10 µg/ml, was determined by Trypan blue 
exclusion.  P. gingivalis did not influence the viability of 
cannabinoid-exposed TIGK cells (all, p > 0.05 compared to the 
untreated control.  
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3.2 Cannabinoid subtypes and the production of pro-inflammatory 
cytokines in LPS & P. gingivalis-stimulated TIGK cells. 
CANNABINOIDS SUPPRESS THE PRODUCTION  OF IL-8 IN LPS & P. 
gingivalis-STIMULATED TIGK CELLS 
 
Bacterial lipopolysaccharides (LPS) are major outer surface 
membrane components present in almost all Gram-negative 
bacteria67. The lipid A portion of LPS is a potent stimulator of innate 
immunity67, 68. Escherichia coli-derived LPS represents the classic 
TLR4-dependent proinflammatory agonist68, 69. IL-8 is a major pro-
inflammatory chemokine that is released by epithelial cells that have 
detected microbial signals that, among other functions, acts as a 
chemoattractant to immune cells, particularly neutrophils70, 71. P. 
gingivalis is a major periodontal pathogen72. It causes perturbation of 
the epithelial cells, invades the periodontal tissue and evades host 
defense mechanisms72. In doing so, it utilizes its panel of virulence 
factors causing deregulation of the innate immune response and 
inflammatory process72, 73. P. gingivalis exists commensally in the 
host and causes a dysbiotic shift of the microbial environment during 
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the disease episodes17. It triggers a wide array of changes in the 
gingival epithelial cells such as selective inhibition of certain immune 
mediators and modulation of signaling pathways causing  
 
dysregulation of innate immune response74. To check the influence of 
marijuana derived cannabinoid subtypes on the release of IL-8, we 
exposed TIGK cells to cannabinoid subtypes followed by LPS or P. 
gingivalis. As shown in Figure 3, cannabinoids (CBD, CBN or THC; 
1 and 5 µg / ml) significantly inhibited the LPS and P. gingivalis-
induced IL-8 response in TIGK cells. 
 
 
                         
                                                      Figure3A 
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                                                      Figure 3B                    
                                    
                                                       Figure 3C 
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FIGURE 3: Cannabinoids suppress IL-8 release in LPS & P. gingivalis-stimulated 
TIGK cells. (A) CBD, (B) CBN or (C) THC, at the concentrations noted, suppressed IL-
8 release in LPS (1µg/ml)-stimulated TIGK cells, as determined in 20 hr cell-free 
supernatants by ELISA. TIGK cells were exposed to cannabinoid subtypes (1 & 
5µg/ml) for 2 hr. followed by addition of LPS (0-1µg/ml) or P. gingivalis [MOI 10:1] 
for 18 hr. Figure 3, shows stats significant variation from P. gingivalis above, however 
LPS also shows significant difference from all points on the graph except for 
CBD1ug/ml +LPS (1µg/ml) & P. gingivalis alone (Figure3A); P. gingivalis alone 
(Figure 3B). */ *** p < 0.5 / 0.001, respectively, compared to the P. gingivalis control. 
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CANNABINOIDS SUPPRESS PRODUCTION OF IL-6 IN IN LPS & P. 
gingivalis- STIMULATED TIGK CELLS 
Periodontal pathogens and bacterial-derived stimulants, including 
LPS, initiate pro-inflammatory changes in the periodontium cytokine 
production75, 76.In the gingiva, IL-6 is produced by mononuclear cells. 
These Macrophages were shown to secrete IL-6 in response to LPS in 
a dosedependent manner77. The association between IL-6 and alveolar 
bone loss in periodontal disease was also established in animal 
models78. IL-6, synergistic with other inflammatory cytokine induces 
bone resorption78, 79. Having established that cannabinoids suppress 
the IL-8 response of TIGK cells, we next examined the influence of 
CBD, CBN and THC on LPS or P. gingivalisinduced secretion of IL-
6 from TIGK cells. As shown in Figure 4, cannabinoids, (CBD, CBN 
or THC; 1 and 5 µg / ml) significantly inhibited the LPS & P. 
gingivalis-induced IL-6 response in TIGK cells in a similar manner to 
IL-8. 
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                                                           Figure 4C  
 
 
 
 
3.3 Cannabinoid subtypes and the production of the anti- 
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FIGURE 4: Cannabinoids suppress IL-6 release in LPS & P. gingivalis-
stimulated TIGK cells.(A) CBD, (B) CBN or (C) THC, at the concentrations 
noted, suppressed IL-6 release in LPS (1µg/ml)-stimulated TIGK cells, as 
determined in 20 hr cell-free supernatants by ELISA.TIGK cells were exposed 
to marijuana derived cannabinoid subtypes at (1 & 5µg/ml) for 2hr , followed by 
LPS(0-1µg/ml) or P. gingivalis [MOI 10:1] for 18hr. Figure 4, shows stats 
significant variation from P. gingivalis above, however LPS also shows 
significant difference from all points on the graph except for P. gingivalis 
alone(Figure 4A); CBN 1µg/ml and P. gingivalis alone (Figure 4B); 
THC1µg/ml + LPS (1µg/ml) (Figure 4C).**/ *** p < 0.01 / 0.001, respectively, 
compared to the P. gingivalis control.  
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Inflammatory cytokine ,IL-10, in LPS & P. gingivalis-stimulated 
TIGK cells 
CANNABINOIDS ENHANCE THE PRODUCTION OF IL-10 IN IN 
LPS & P. gingivalis STIMULATED TIGK CELLS 
Bacterial stimuli-induced cytokines play a major role in the 
progression of chronic periodontitis80. Earlier, we considered the pro-
inflammatory cytokines, IL-6 and IL-8. However, it is the balance of 
pro- and anti-inflammatory mediators that determine the severity, 
duration and direction of innate responses81. IL-10 is a key anti-
inflammatory cytokine that has been shown to have osteoprotective 
properties82. P. gingivalis is known to be a major periodontal 
pathogen associated with chronic periodontitis. IL-10 is an anti-
inflammatory cytokine known to have an important function in 
balancing the effects of the pro-inflammatory cytokines, thus 
modulating the progression of the chronic inflammation and 
exacerbation of the disease state81. Therefore, we next determined the 
influence of marijuana derived cannabinoid subtypes on the release of 
IL-10 from LPS and P. gingivalis-stimulated TIGK cells. As shown 
in Figure 5 cannabinoids (CBD, CBN or THC; 1 and 5 µg / ml) 
significantly enhanced the LPS and P. gingivalis induced IL-10 
response in TIGK cells. 
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FIGURE 5: Cannabinoids enhance IL-10 release in LPS & P. gingivalis-
stimulated TIGK cells.  
(A) CBD, (B) CBN or (C) THC, at the concentrations noted, enhanced IL-10 
release in LPS (1µg/ml)-stimulated TIGK cells, as determined in 20 hr cell-free 
supernatants by ELISA. TIGK cells were exposed to marijuana derived 
cannabinoid subtypes at (1 & 5µg/ml) for 2hr, followed by LPS (0-1µg/ml) or P. 
gingivalis [MOI 10:1] for 18hr. Figure 5, shows stats significant variation from 
P. gingivalis above, however LPS also shows significant difference from all 
points on the graph except for CBD1µg/ml, CBD 5µg/ml, negative control & 
P.gingivalis (Figure 5A); P. gingivalis (Figure 5B).THC 1µg/ml, THC 5µg/ml 
and P. gingivalis (Figure 5C). **/ *** p < 0.01 / 0.001, respectively, compared to 
the P. gingivalis control.  
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3.6 Pharmacological inhibition of CB2 
THE CB2 INHIBITOR, JTE 907, FAILS TO RESCUE THE 
PRODUCTIONOF IL-8 or IL-6 IN TIGK CELLS 
 
We hypothesized that the anti-inflammatory effect of the cannabinoid 
subtypes are mediated through epithelial CB2 receptors. In order to 
confirm this hypothesis, we used a specific pharmacological inhibitor 
of CB2, JTE90783, at a concentration of 5µg/ml. TIGK cells were 
pretreated with JTE907 (5µg/ml) for 30min. Therefore, we next 
determined the influence of marijuana derived cannabinoid subtypes 
on the release of pro-inflammatory cytokine IL-8 and IL6 from P. 
gingivalis-stimulated TIGK cells pretreated with JTE 907. As shown 
in Figures 6 and 7, JTE907 failed to rescue IL-8 production in LPS- 
or P. gingivalis stimulated TIGKs. Similarly, as shown in Figures 8 
and 9, JTE907, failed to rescue IL-6 production in LPS- or P. 
gingivalisstimulated TIGKs. These data imply that CB2 is not the 
surface receptor responsible for cannabinoid initiated anti-            
inflammatory signals in gingival epithelial cells. 
45 
 
                             
      Figure 6A                      Figure 6B                               Figure6C 
                                                            
      Figure 7A                         Figure 7B                             Figure 7C                                                                                                                                              
          
 
 
 
 
 
 
FIGURES 6 and 7: Pretreatment with a specific CB2 inhibitor fails to rescue IL-8 
release in P. gingivalis- and LPS -stimulated TIGK cells.   
(A) CBD, (B) CBN or (C) THC, at the concentrations noted, suppressed IL-8 
release in (Figure 9) LPS- and (Figure 10) P. gingivalis-stimulated TIGK cells. IL-8 
production in TIGK cells pretreated with the CB2 inhibitor, JTE907 (5 µg/ml 30 
mins), was also determined. TIGK cells were exposed to JTE-907 for 30 mins 
followed by cannabinoid subtypes (1& 5 µg/ml) for 2hr and then to LPS (1µg/ml) 
or P. gingivalis (MOI of 10:1) for 18hr. **/ *** p < 0.01 / 0.001, respectively, 
compared to the LPS (Figure 9) or P. gingivalis only controls.  
 
46 
 
 
Figure 8A                     Figure 8B                               Figure 8C 
 
Figure 9A                                     Figure 9B                                 Figure 9C 
 
 
 
 
 
 
 
 
 
 
 
         
             
FIGURES 8 and 9: Pretreatment with a specific CB2 inhibitor fails to rescue 
IL-6 release in P. gingivalis- and LPS -stimulated TIGK cells.  
(A) CBD, (B) CBN or (C) THC, at the concentrations noted, suppressed IL-6 
release in (Figure 11) LPS- and (Figure 12) P. gingivalis-stimulated TIGK 
cells. IL-6 production in TIGK cells pretreated with the CB2 inhibitor, 
JTE907 (5 µg/ml 30 mins), was also determined. TIGK cells were exposed to 
JTE-907 for 30 mins followed by cannabinoid subtypes (1& 5 µg/ml) for 2hr 
and then to LPS (1µg/ml) or P. gingivalis (MOI of 10:1) for 18hr.*/**/ *** p 
< 0.05 / 0.01 / 0.001, respectively, compared to the LPS (Figure 9) or P. 
gingivalis only controls.  
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3.7 The influence of cannabanoids on the growth of select oral pathogens 
 HIGH DOSES OF CANNABINOIDS SUPPRESS THE GROWTH  
OF P.GINGIVALISAND F. ALOCIS BUT NOT T. DENTICOLA 
 
To check the effect of cannabinoid subtypes on the viability of the 
major representative oral periodontal pathogens like P. gingivalis, F. 
alocis & T. denticola. We exposed these bacterial cultures to the 
noted concentrations of the cannabinoid subtypes and plotted the 
growth bacteria was grown in their respective culture medium. P. 
gingivalis was grown in GAM supplemented, or not, with 
cannabinoid subtypes cannabinol, cannbidiol and 
tetrahydrocannabinol at concentrations of 0.1, 1, 5 & 10 µg/ml and 
growth monitored by absorbance measurements at O.D. 600 nm. As 
shown in Figure 10, higher doses of cannabinoids (CBD, CBN or 
THC) inhibited the growth of P. gingivalis. Similar results were noted 
for F. alocis (see Figure 11), wheras T.denticola was resistant to all 
cannabinoid doses tested (see Figure 12). 
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       Figure 10A                   
Figure 10B                        
                   
       Figure 10 C 
                             
FIGURE 10: High dose cannabinoids suppress the growth of the 
periodontal pathogen, P. gingivalis. P.gingivalis was grown in GAM 
supplemented, or not, with (A) CBD, (B) CBN or (C) THC, at the 
concentrations noted, and growth monitored by absorbance measurements at 
O.D. 600 nm.*/**/ *** p < 0.05 / 0.01 / 0.001, respectively, compared to 
control. 
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         Figure 11A                                            Figure 11B        
                                             
  
                                                    Figure 11C 
 
 
 
 
FIGURE 14: Cannabinoids do not influence to growth of T. denticola. 
T. denticola   was grown in TYGVS medium supplemented, or not, with (A) CBD, (B) 
CBN or (C) THC, at the   concentrations noted, and growth monitored by 
absorbance measurements at O.D. 600 nm. There were no statistically significant 
differences in the growth characteristics of cannabinoid -exposed and control bacteria 
(all, p > 0.05 compared to the untreated control). 
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Figure 12A                                               Figure 12B                                          
 
Figure 12C                                         
 
FIGURE 12: High dose cannabinoids suppress the growth of the periodontal 
pathogen, F.  alocis. 
F. alocis   was grown in BHI supplemented, or not, with (A) CBD, (B) CBN or 
(C) THC, at the concentrations noted, and growth monitored by absorbance 
measurements at O.D. 600 nm. 
 
*/ *** p < 0.05 / 0.001, respectively, compared to control 
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CHAPTER 4 DISCUSSION  
Cannabis use has been etiologically associated with periodontal 
disease susceptibility, but the underlying mechanisms are unknown61, 
62. We have established that (i) high doses of marijuana derived 
cannabinoids negatively influence the viability of TIGK cells; (ii) 
sub-toxic doses of cannabinoids suppress pro-inflammatory cytokine 
production by TIGK cells responding to LPS or to P. gingivalis; (iii) 
sub-toxic doses of cannabinoids enhance anti-inflammatory IL-10 
production by TIGK cells responding to LPS or to P. gingivalis; (iv) a 
normal innate response to bacterial stimuli is not rescued by 
pharmacological inhibition of CB2 in TIGK cells; and that (v) high 
doses of cannabinoids inhibit the growth of P. gingivalis and F. alocis 
but not T. denticola. 
Should these five phenomena occur in the oral cavity of human 
cannabis users, then we start to explain how marijuana, specifically 
marijuana-derived cannabinoids, may predispose to chronic 
periodontitis and/ or other periodontal diseases. 
The oral epithelial barrier separates the host from the environment 
and provides the first line of defense against pathogens, exogenous 
substances and mechanical insults84. It consists of underlying 
connective tissue and a stratified keratinized epithelium with at 
membrane, whose cells undergo terminal differentiation resulting in 
52 
 
the formation of a mechanically resistant surface. Gingival 
keratinocytes are connected by various transmembrane proteins, such 
as tight junctions, adherens junctions and gap junctions, each of 
which has a specialized structure and specific functions84. Periodontal 
pathogens are able to induce inflammatory responses that lead to 
attachment loss and periodontal destruction. A number of studies 
have demonstrated that the pathogenic oral bacteria influence the 
expression and structural integrity of different cell-cell junctions37. 
Tissue destruction can be mediated by host cells following 
stimulation with cytokines and bacterial products75.To summarize, the 
oral epithelium is able to react to a variety of exogenous, possibly 
noxious influences.  
Thus an intact oral epithelial barrier is a key component of the host 
oral defense system. In consonance to the findings in our study, we 
observe that the higher concentrations of marijuana derived 
cannabinoid subtypes proved to have a negative effect on gingival 
epithelial cell viability hence compromising the intactness of the 
epithelial layer required for the initial host defense to periodontal 
pathogens. It is possible that cannabinoid induced epithelial cell death 
may compromise the integrity of this junctional epithelium layer, 
facilitating breach by periodontal pathogens and, more importantly, 
by bacterial-derived toxins known to contribute to the disease process 
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in chronic periodontitis. This may explain the predisposition of 
chronic periodontitis in marijuana users. 
As we know, the etiology of periodontal diseases is bacterial. The 
human oral cavity harbors an evolving load of microbial species. The 
ecological interactions between the host and oral microbes determine 
the severity of the disease process. The critical interplay between the 
host immune mechanisms and inflammatory responses determine the 
pathogenesis of complex diseases like chronic periodontitis70. The 
immunological events seem to overlap during different phases of the 
disease thus making the understanding of the pathogenesis of the 
disease difficult. 
The metabolic products of bacteria trigger junctional epithelium cells 
to produce cytokines. The acute inflammation, is the physiologic 
response to the microbial challenge to recruit adequate immune cells 
to site of infection through the production of cytokines and 
chemokines85, 86.Innate immunity is usually, characterized by the 
phagocytosis and digestion of microorganisms and foreign substances 
by macrophages and neutrophils86. Phagocytes such as macrophages 
and neutrophils have surface receptors that recognize and bind 
surface molecules of bacteria86. Thus these cytokines are seen to play 
a protective role by helping to recruit immune cells to the site of the 
inflammation87, 88. The host responds to microbial challenge by 
generating an inflammatory cell infiltrate in the tissue subjacent to the 
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periodontal pocket70.The cytokines and chemokines forms an integral 
part of the initial innate immune response, they signal the submucosal 
effector molecules leading to the activation of inflammatory signaling 
pathways like NF-kB89. Cytokines are produced by resident cells, 
such as epithelial cells and fibroblasts, and by phagocytes 
(neutrophils and macrophages) in the acute and early chronic phases 
of inflammation70. 
The first cytokine identified to have chemotactic activity was 
interleukin-8. In the periodontium, this cytokine is produced primarily 
by gingival fibroblasts, gingival epithelial cells and endothelial 
cells90. Interleukin-8 is a polymorphonuclear leukocyte 
chemoattractant71. It is detectable in healthy and diseased periodontal 
tissues and has been associated with subclinical inflammation of the 
initial phase of the disease which is comprised of polymorphonuclear 
neutrophil gradient along the intact junctional epithelium. Prior 
studies have established that P. gingivalis evade and disrupt the host 
immune homeostasis contributing to the exacerbation of the disease 
process in chronic periodontitis91. It has also been established that P. 
gingivalis produce gingipains a potent virulence factor which causes 
inactivation of pro-inflammatory cytokine IL-892. This implies that 
the periodontal pathogen survives longer evading the immune 
response, contributing to polymicrobial dysbiosis of the periodontal 
community17. Interleukin-6 is another pro-inflammatory cytokine 
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which is one of the first few cytokines to appear in the periodontal 
disease pathogenesis and is known to play an important part in the 
progression of the chronic periodontitis. Interleukin-6 is an innate 
cytokine which has been associated with inflammatory cell migration 
and osteoclastogenesis in chronic periodontitis93. 
In accordance to the prior studies, in our study we observe that the 
marijuana derived cannabinoid subtypes abrogate production of pro-
inflammatory cytokine IL-8 and IL-6 from LPS or P. gingivalis 
stimulated TIGK cells. It may imply that the abrogation of these 
cytokines would dysregulate the first line of innate immune response 
in the epithelial cells. Cells pertaining to innate immunity like 
neutrophils and macrophages would no longer be able infiltrate at the 
site of inflammation. Hence the periodontal pathogen would be able 
to survive for a longer period of time and secrete potent proteolytic 
enzymes like proteases which would further accentuate the 
destruction of the periodontium. The result of our study confirms the 
well-established anti-inflammatory property of cannabinoids and how 
it supports the suppression of the innate immune response explaining 
the increasing susceptibility of marijuana users to chronic 
periodontitis. Furthermore, suppression of inflammation, if it also 
occurs in vivo, implies that clinicians may need to increase screening 
vigilance in order to detect the onset of periodontal tissue destruction 
in cannabis smokers with a suppression of clinical signs of 
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inflammation with response down regulation of pro-inflammatory 
cytokines. 
The role of pro-inflammatory cytokines in the periodontal tissue 
destruction is well documented in the animal model94. However, 
cellular responses to the pro-inflammatory cytokines are regulated 
negatively by anti-inflammatory cytokines and the balance between 
these two categories of cytokine could be important in the outcome of 
inflammatory response81. The prior studies showed that anti-
inflammatory cytokine IL-10 was suppressed by pro-inflammatory 
cytokine in chronic periodontitis95. The studies also showed that the 
difference of pro and anti-inflammatory cytokine (IL-10) in 
periodontitis was very subtle but significant to cause destruction of 
the periodontal structures in chronic periodontitis81. It was noted in 
our study that there was concomitant rise in the expression of anti-
inflammatory cytokine IL-10 from LPS/ P. gingivalis stimulated 
TIGK cells when exposed to marijuana derived cannabinoid subtypes 
at sub-lethal doses. The findings of our study does not seem to be in 
accordance to the prior studies .The elevated levels of IL-10 on 
exposure to cannabinoids in epithelial cells  implies that marijuana 
derived cannabinoids although are implicated as a risk factor for 
chronic periodontitis they suppress pro-inflammatory cytokine and 
increases the anti-inflammatory ones which is opposite to the pattern 
usually observed in earlier studies involving chronic periodontitis95.It 
57 
 
is possible that cannabinoid induced suppression of pro–inflammatory 
cytokines may prevent the recruitment of immune cells like 
neutrophils which is a spontaneous reaction of the innate immune 
mechanism and  up regulation of  IL-10 further  contributes in 
suppressing the pro-inflammatory cytokines(cellular crosstalk) 
preventing the initial  innate inflammatory response. Thus helping the 
disease associated pathogen to evade the immune response. As 
cannabinoids are known to be anti-inflammatory it is possible that it 
plays a role in upregulating the expression of anti-inflammatory 
cytokine IL-10. It has been shown in prior studies that IL-10 and 
cannabinoids have an osteo-protective effect82, 96.Therefore it is 
necessary to research further in this direction to gain a mechanistic 
insight that would explain the osteo-protective influence of 
cannabinoid subtypes in context to its anti-inflammatory property in 
chronic periodontitis model. 
It has been noted previously that CB2 is expressed in the gingival 
epithelial cells comprising the junctional epithelium59, 60. We had 
hypothesized that the anti-inflammatory actions of cannabinoids may 
be mediated through such surface CB2 receptors. It was noted that 
pharmacological inhibition of CB2 receptor did not rescue the innate 
immune response to bacterial stimulants in epithelial cells. Further 
research would be needed to understand the functional importance of 
the CB2 receptor. Other specific inhibitor like AM630, along with 
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siRNA-mediated CB2 gene silencing, could be used to determine the 
importance of CB2 in cannabinoid-mediated suppression of the innate 
response to dental plaque pathogens in hum an gingival epithelial 
cells. CB2 expression could be also studied using q PCR telling us 
more about the m-RNA levels. 
It is also possible that the JTE907 results are genuine, therefore the 
anti-inflammatory action of cannabinoids may be brought about by 
other non-CB2 target receptors. Therefore creating a scope of 
studying other potential target receptors like the CB1, GPR55 and 
A2A receptors which may be associated with the anti-inflammatory 
function of marijuana derived cannabinoids97, 98. 
Finally, the findings that P. gingivalis and F. alocis, but not T. 
denticola, are susceptible to cannabinoids is both novel and 
intriguing. Essentially, clinically healthy periodontal tissue maintains 
a highly ordered, mild state of inflammation70. It is usually 
established that the normal oral microflora, which is thought to 
provide the stimulus for this mild inflammatory response. However, 
the highly ordered state of mild inflammation is replaced by a 
disordered state of severe inflammation with the altered microbial 
community14.  As seen that suppression and negative influence of 
marijuana derived cannabinoid subtypes on periodontal pathogen P. 
gingivalis and F.alocis seem to alter the periodontal microbial 
community. Thus, it is proposed that the shift from a symbiotic 
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microflora to a dysbiotic pathogenic community triggers the potent 
host inflammatory response that contributes to the tissue destruction 
and alveolar bone loss that are characteristic of periodontitis17. 
There are a number of limitations to this study. It is possible that 
cytokine release in response to E. coli LPS, used as a positive control 
in much of the experiments herein, may have been optimized with the 
addition of serum as soluble CD14 is present in serum  and facilitates 
binding of LPS .Binding of LPS to CD14 is enhanced by the presence 
of the LPS binding protein (LBP)99.LBP may also enhance binding of 
whole Gram-negative bacteria to cells thus transferring LPS to a 
second receptor that directly transduces the signal thus or by the use 
of protease inhibitors, that would stabilize cytokines produced. 
Further, we did not monitor the activity of cytokine-encoding genes. 
In the future, further research could be carried out to analyze the 
complex signaling pathways associated in cannabinoid-induced 
suppression of innate immunity in epithelial cells. The information 
generated would be further used in gingival epithelial cells, other 
innate cell types, and additional pathogen strains as well as the 
establishment of in vivo relevance in mouse models of periodontitis 
and inflammation. 
In summary, cannabinoids exert multiple negative effects on 
epithelial viability, on epithelial responses to bacterial stimuli and on 
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bacterial growth characteristics. In concert, these events are likely to 
predispose individuals who smoke marijuana to periodontal diseases. 
Further delineation of marijuana-periodontal disease interactions may 
be warranted. Determination of the amount of cannabinoids found in 
the gingival crevice of cannabis users; the mechanisms of 
cannabinoid induced epithelial death; the signaling pathways 
controlling innate immune suppression; and the influence of cannabis 
intake on the periodontal microbiome are all likely to provide useful 
information helping to explain how marijuana induces and/or 
exacerbates periodontal diseases. Such insights are needed for the 
development of novel therapeutic and preventive approaches for this 
growing section of American society. 
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